Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...

Related Keywords

Paris ,France General ,France ,China ,Massachusetts ,United States ,Georged Yancopoulos ,Hannah Kwagh ,Timothy Gilbert ,Regeneron Velocimmune ,Nathalie Pham ,Sandrine Guendoul ,Evan Berland ,Felix Lauscher ,Arnaud Delepine ,Thomas Kudsk Larsen ,Tarik Elgoutni ,Corentine Driancourt ,Vesna Tosic ,Clinical Research Program ,Us Department Of Justice ,Linkedin ,European Commission ,Nasdaq ,Exchange Commission ,European Union ,Dupilumab Development Program ,European Commission Of Dupixent ,Facebook ,Regeneron Genetics Center ,Instagram ,Globenewswire Inc ,Drug Administration ,Regeneron Pharmaceuticals Inc ,Euronext ,European Medicines Agency ,Medicinal Products ,Human Use ,Respiratory Questionnaire ,Priority Review ,Biologics License Application ,Chief Scientific Officer ,Nasal Polyposis ,Prescribing Information ,Regeneron Genetics ,Forward Looking Statements ,Medicines Agency ,Product Candidates ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,